Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127676 | 1.00 | CYP2B6 (0.59) | CYP2B6CHRM3NPSR1 | |
| SCHEMBL3043721 | 1.00 | CYP2B6 (0.59) | CYP2B6CHRM3NPSR1 | |
| SCHEMBL4444477 | 1.00 | CYP2B6 (0.59) | CYP2B6CHRM3NPSR1 | |
| SCHEMBL7592805 | 0.98 | CHRM3 (0.57) | CYP2B6CHRM3 | |
| SCHEMBL4738180 | 0.88 | CYP2B6 (0.58) | CYP2B6CHRM3NPSR1 | |
| SCHEMBL6266546 | 0.86 | CYP2B6 (0.56) | CYP2B6CHRM3NPSR1 | |
| SCHEMBL26698239 | 0.84 | CHRM3 (0.55) | CHRM3 | |
| SCHEMBL2127682 | 0.83 | CHRM3 (0.61) | CYP2B6CHRM3 | |
| SCHEMBL1682974 | 0.83 | CHRM3 (0.61) | CYP2B6CHRM3 | |
| SCHEMBL2126929 | 0.83 | CHRM3 (0.61) | CYP2B6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121137-B1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| CN-101610813-A | Quinuclidinol derivatives as muscarinic receptor antagonist | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2121137-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075006-A1 | PIPERLDINUM COMPOUNDS FOR TREATMENT OF OBSTRUCTIVE PULMONARY DISEASES ( COPD) | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075005-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | CYP2B6 2982/4885CHRM3 656/4885NPSR1 1560/4885 |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CYP2B6 401/4885CHRM3 3/4885NPSR1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.